Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Blood Cells Mol Dis. 2015 Oct 27;56(1):62–69. doi: 10.1016/j.bcmd.2015.10.004

Figure 6. Activation markers of histone modification (H3AcK9 & H3K4me2) in the γ-globin gene promoter in HbE β-thalassemia progenitors treated with Benserazide (BEN).

Figure 6

H3K4me2 and H3AcK9 enrichment in the γ-globin gene promoter is shown in Benserazide-treated HbE β-thalassemia progenitors and vehicle-treated control. The error bars represent the SEM. Asterisks indicate significant differences between the vehicle controls and Benserazide-treated cells (*p<0.05).